NCT05403580View on ClinicalTrials.gov

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 3, 2022

Primary Completion Date

December 29, 2023

Study Completion Date

December 31, 2024

Conditions
Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
Interventions
DRUG

Olanzapine

Given PO

DRUG

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05403580 - Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter